



Leonard Zon, MD
Director, Stem Cell Program
1 Blackfan Circle, Karp 5211
Boston, MA 02115
617-919-2069
zon@enders.tch.harvard.edu



May 9, 2024

Re: Application Number: TRAN4-15225

Dear Committee,

I understand that Irv Weissman has put together a very interesting grant to test the hypothesis that using CD34+ and CD90+ selection for CD34+90+ dual positive HSC, which are cancer free and T cell free blood stem cells could lead to transformative clinical results for cancer therapy. In particular, this would allow depletion of any contaminating tumor cells from the marrow. These antibodies were created years ago, but have not been able to be evaluated clinically due to patent issues. It seems that these issues have been solved and the therapy deserves to be evaluated. I am enthusiastic about this proposal, and agree that CD34 selected cells are no substitute, as they are not cleared of either cancer cells or T cells.

Sincerely,

A handwritten signature in black ink that reads "Leonard I. Zon MD".

Leonard I. Zon, M.D.
Director, Stem Cell Program, Boston Children's Hospital
Grousbeck Professor of Pediatrics, Harvard Medical School
Investigator, Howard Hughes Medical Institute